Fremanezumab (Ajovy) vs Galcanezumab (Emgality)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP ligand · full Migraine pipeline

Fremanezumab (Ajovy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Migraineantibody
Partial signal

NCT02638103 · Phase 3 · completed

This was a large, quadruple-masked rollover/extension study continuing participants from two prior fremanezumab randomized trials, with placebo-matched injections used to preserve masking across monthly and quarterly regimens. Its primary outcomes were descriptive safety measures, and the study did not report a formal placebo-controlled primary efficacy comparison, so it provides useful but limited evidence for fremanezumab.

Reported efficacy

Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug (Baseline (Day -28 to Day -1), up to Week 12): Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). (met)

Result source: NCT04458857

Galcanezumab (Emgality)

Marketed by Eli Lilly and partners

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02614261 · Phase 3 · completed

The main treatment phase was a large, randomized, double-blind, placebo-controlled trial with 1,117 participants. Its clinical primary endpoint was met: both galcanezumab doses produced a statistically significant greater reduction in monthly migraine headache days than placebo.

Next expected readout: July 2031 · NCT07655440 (registry estimate)

Reported efficacy

Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. (Baseline, 3 Months): Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. (met)

Result source: NCT03963232

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fremanezumab (Ajovy)
Change in monthly migraine days over 12 weeks (median): fremanezumab 675 mg quarterly -4.0 and 225 mg monthly -4.2 vs placebo -2.7; both p<0.0001 (Wilcoxon) (CT.gov posted results). NCT02629861 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). NCT04458857 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results). NCT02621931 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Galcanezumab (Emgality)
Change in monthly migraine headache days over months 1 to 3 (chronic migraine), LS mean -4.83 (120 mg) and -4.62 (240 mg) vs -2.74 (placebo); difference vs placebo 120 mg -2.09 days (95% CI -2.92 to -1.26), 240 mg -1.88 days (95% CI -2.71 to -1.05), both p<.001. NCT02614261 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine headache days over months 1 to 6, LS mean -4.73 (120 mg) and -4.57 (240 mg) vs -2.81 (placebo); difference vs placebo 120 mg -1.92 days (95% CI -2.48 to -1.37), 240 mg -1.76 days (95% CI -2.31 to -1.20), both p<.001. Met at both doses. NCT02614183 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine headache days over months 1 to 6, LS mean -4.29 (120 mg) and -4.18 (240 mg) vs -2.28 (placebo); difference vs placebo 120 mg -2.02 days (95% CI -2.55 to -1.48), 240 mg -1.90 days (95% CI -2.44 to -1.36), both p<.001. Met at both doses. NCT02614196 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. NCT03963232 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001. NCT03559257 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fremanezumab (Ajovy)'s landscape · Galcanezumab (Emgality)'s landscape